Aprea Therapeutics to collaborate with Memorial Sloan Kettering cancer center
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.